News Releases
- August 20, 2020Annovis Bio Actively Recruiting Patients for its Phase 2a Trials in Alzheimer’s and Parkinson’s Diseases
- July 23, 2020Annovis Bio CEO Appears on Executive Leaders Radio Program
- July 20, 2020Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
- July 7, 2020Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients
- June 16, 2020Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
- June 9, 2020Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit
- June 2, 2020Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401
- June 1, 2020Annovis Bio 2020 Annual Meeting of Stockholders to Be Held on June 3, 2020
- May 27, 2020Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19
- May 1, 2020Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
- May 4, 2022Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
- April 28, 2022Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
- April 11, 2022Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Media Coverage
- March 11, 2022Biotech IQ Podcast: Is axonal transport the key to solving neurodegenerative diseases? Maria Maccechini, PhD - CEO, Annovis Bio
- February 24, 2022Alzhemier's Speaks Radio: Annovis, a Biotech Company, Shares Updates on Their Research
- February 04, 2022Finding Genius Podcast: Understanding Neurodegenerative Diseases and the Links Between Parkinson"s and Alzheimer"s Disease with Dr. Cheng Fang
Events & Presentations
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top